In a recent interview with Sky News, the CEO, Stephane Bancel, disclosed that Moderna is planning a new mRNA vaccine to repair heart muscles after a heart attack.
- EXPLOSIVE: Here’s what was uncovered in Hunter Biden’s iCloud Hack
- MAJOR PEER REVIEWED STUDY: Moderna Vaccine Increases Myocarditis Risk By 44 Times In Young Adults
- MUST READ: High Level International Bankers Simulate The Collapse Of Global Financial System
- BIG STORY: Wuhan Lab Isolated Monkeypox Strain In 2020
- EXPLOSIVE: Ukraine Biolabs Used Fever Carrying Mosquitoes To Spark Dengue Pandemic In Cuba
Moderna’s CEO disclosed that his company has a programme that involves administering messenger RNA (mRNA) to patients’ hearts after a heart attack.
In a recent interview with Sky News, the CEO, Stephane Bancel, said, “We are now in a super exciting programme where we inject mRNA in people’s hearts after a heart attack to grow back new blood vessels and re-vascularize the heart.”
Bancel gave no further details about the program’s design. One of the most widely used mRNA vaccines for COVID-19 was created by his company, along with pharmaceutical giant Pfizer.
Bancel concurred when the reporter suggested that the COVID-19 pandemic had a “irony” in that it had enabled companies like Moderna to “develop these other areas because of the revenues that came through the door.” “You’re 100 percent right,” he said.
Subscribe to GreatGameIndia
Enter your email address to subscribe to GGI and receive notifications of new posts by email.
Moderna reported $4.7 billion in revenue for the second quarter of 2022 in August, an increase of $300 million from the same period in 2021. Its overall revenue for the first half of this year was $10.8 billion, up from $6.3 billion during the same period previous year.
The company claimed the sharp increase in sales of its COVID-19 vaccination as the cause of its significant revenue gain.
No mRNA products in the United States had achieved full FDA approval prior to the U.S. Food and Drug Administration (FDA) issuing emergency use authorizations for the Moderna and Pfizer COVID-19 vaccines in 2020.
Officials claim that mRNA-based therapies will reduce inflammation in connection with three major heart diseases, including atherosclerosis, pulmonary hypertension, and abdominal aortic aneurysm. In the meantime, an Australian government agency last month granted $1.1 million to target three major cardiovascular diseases using mRNA technology.
“The mRNA-based targeted strategies that we are investigating can stop the progression of inflammation, providing the opportunities of preventing cardiovascular disease events like heart attack, stroke, and heart failure without the unwanted side effects,” one researcher, Baker Institute’s head of molecular imaging and theranostics Xiaowei Wang, said in a statement after the grant.
According to Wang, scientists will develop a “unique delivery system using novel nanoparticles” to “trigger the release of the mRNA” for the three cardiovascular diseases.
However, a pre-print study published in August claimed that the COVID-19 vaccine’s mRNA-transporting nanoparticles suppressed and altered the immune response.
At the same time, Florida’s Surgeon General Joseph Ladapo said earlier this week that males between the ages of 18 and 39 should not receive the mRNA COVID-19 vaccine. He quoted a state investigation that showed an 84% rise in the relative incidence of cardiac-related mortality in men in that age range 28 days after receiving an mRNA vaccination.
This content was originally published here.